Trial Profile
Multicenter Phase II Study of Axitinib in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AXIPAP
- 13 Sep 2022 Results of post-hoc analysis presented at the 47th European Society for Medical Oncology Congress.
- 05 Mar 2020 Results published in the European Journal of Cancer
- 19 Feb 2020 Status changed from active, no longer recruiting to completed.